Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 2/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27673086 | 0.90 | MCL1 (0.53) | DAOMCL1ALDH1A1TSHRCCR2 | |
| SCHEMBL10775990 | 0.90 | CCR2 (0.57) | DAOMCL1ALDH1A1TSHRCCR2 | |
| SCHEMBL4445494 | 0.81 | MCL1 (0.62) | DAOMCL1ALDH1A1TSHRCCR2 | |
| SCHEMBL30304240 | 0.78 | DAO (0.54) | DAOMCL1ALDH1A1TSHRCCR2 | |
| SCHEMBL22396277 | 0.78 | DAO (0.54) | DAOMCL1ALDH1A1TSHRCCR2 | |
| SCHEMBL30844614 | 0.78 | DAO (0.54) | DAOMCL1ALDH1A1TSHRCCR2 | |
| SCHEMBL30310709 | 0.78 | MCL1 (0.57) | DAOMCL1ALDH1A1TSHRCCR2 | |
| SCHEMBL5002608 | 0.78 | DAO (0.54) | DAOMCL1ALDH1A1TSHRCCR2 | |
| SCHEMBL4542678 | 0.78 | MCL1 (0.57) | DAOMCL1ALDH1A1TSHRCCR2 | |
| SCHEMBL7492984 | 0.76 | CCR2 (0.57) | DAOMCL1ALDH1A1TSHRCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
| EP-0249885-A2 | Heat-sensitive recording material | KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) | 1987-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | DAO 2243/4885MCL1 2195/4885ALDH1A1 1647/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | DAO 2209/4885MCL1 2202/4885ALDH1A1 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.